{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:46:17Z","timestamp":1775544377985,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiolipomas have been well described in patients with HIV exposed to protease inhibitors with possible resolution after switching to non-nucleoside reverse transcriptase inhibitor-based regimens. Resolution of symptoms have occurred with switches to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens; however, little is known regarding the development of angiolipomas when switching from NNRTI- to modern, integrase strand transfer inhibitor-based regimens. We describe a patient who underwent switch therapy from tenofovir disoproxil fumarate\/emtricitabine\/efavirenz (TDF\/FTC\/EFV) to tenofovir alafenamide\/FTC\/bictegravir (TAF\/FTC\/BIC) who later developed angiolipomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 55-year-old male had been on TDF\/FTC\/EFV for 8 years before switching to TAF\/FTC\/BIC. Nineteen months after antiretroviral switch, the patient presented with multiple lesions in the upper extremities and abdomen. Diagnostic biopsies revealed non-encapsulated angiolipomas and HHV-8 and non-alcoholic fatty liver disease was ruled out. New lesions continued to appear 29 months after ART switch, after which now lesions appeared and prior lesions remained stable with no increase in size noted. No surgical intervention or change in antiretroviral therapy was needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Angiogenesis may have been suppressed with TDF\/FTC\/EFV treatment, however when switched to TAF\/FTC\/BIC, promoted the growth of angiolipomas. Clinicians should be aware of the impact of switching to modern ART therapies resulting in possible adipogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-024-00620-9","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:06:58Z","timestamp":1715407618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angiolipoma associated with antiretroviral switch therapy: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Gregory H.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha Sheth","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"issue":"6","key":"620_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/medicina56060283","volume":"56","author":"V Reiser","year":"2020","unstructured":"Reiser V, Haj Yahya B, Chaushu G, Kaplan I, Hamzani Y. Angiolipoma in the head and neck: imaging, diagnosis and management. Med (Kaunas). 2020;56(6):283. https:\/\/doi.org\/10.3390\/medicina56060283.","journal-title":"Med (Kaunas)"},{"issue":"4","key":"620_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/QAD.0b013e3282f56b7a","volume":"22","author":"M Blanes","year":"2008","unstructured":"Blanes M, Boix V, Belinch\u00f3n I, Portilla J. Angiolipomas, a rare manifestation of HIV-associated lipodystrophy. AIDS. 2008;22(4):552\u20134. https:\/\/doi.org\/10.1097\/QAD.0b013e3282f56b7a.","journal-title":"AIDS"},{"issue":"5","key":"620_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/00002030-200203290-00024","volume":"16","author":"E Daud\u00e9n","year":"2002","unstructured":"Daud\u00e9n E, Alvarez S, Garc\u00eda-D\u00edez A. Eruptive angiolipomas associated with antiretroviral therapy. AIDS. 2002;16(5):805\u20136. https:\/\/doi.org\/10.1097\/00002030-200203290-00024.","journal-title":"AIDS"},{"issue":"1Pt1","key":"620_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0190-9622(00)90021-5","volume":"42","author":"JP Dank","year":"2000","unstructured":"Dank JP, Colven R. Protease inhibitor-associated angiolipomatosis. J Am Acad Dermatol. 2000;42(1Pt1):129\u201331. https:\/\/doi.org\/10.1016\/s0190-9622(00)90021-5.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"620_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","volume":"6","author":"JR Koethe","year":"2020","unstructured":"Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48. https:\/\/doi.org\/10.1038\/s41572-020-0181-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"620_CR6","doi-asserted-by":"publisher","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","volume":"8","author":"BR Wood","year":"2021","unstructured":"Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis. 2021;8(12):ofab542. https:\/\/doi.org\/10.1093\/ofid\/ofab542. eCollection 2021 Dec.","journal-title":"Open Forum Infect Dis"},{"issue":"15","key":"620_CR7","doi-asserted-by":"publisher","first-page":"15130","DOI":"10.1074\/jbc.M312875200","volume":"279","author":"K El Hadri","year":"2004","unstructured":"El Hadri K, Glorian M, Monsempes C, Dieudonn\u00e9 MN, Pecquery R, Giudicelli Y, Andreani M, Dugail I, F\u00e8ve B. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279(15):15130\u201341. https:\/\/doi.org\/10.1074\/jbc.M312875200.","journal-title":"J Biol Chem"},{"issue":"2","key":"620_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.antiviral.2011.04.018","volume":"91","author":"J D\u00edaz-Delf\u00edn","year":"2011","unstructured":"D\u00edaz-Delf\u00edn J, del Mar Guti\u00e9rrez M, Gallego-Escuredo JM, Domingo JC, Gracia Mateo M, Villarroya F, Domingo P, Giralt M. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011;91(2):112\u20139. https:\/\/doi.org\/10.1016\/j.antiviral.2011.04.018.","journal-title":"Antiviral Res"},{"key":"620_CR9","doi-asserted-by":"publisher","first-page":"e00909","DOI":"10.1016\/j.idcr.2020.e00909","volume":"21","author":"J Braganza","year":"2020","unstructured":"Braganza J, Aljwaid A, Alazzawi M, Alshami A, Patel NS. Bilateral facial cutaneous angiomyolipomas: first case in the literature and a possible correlation with human immunodeficiency virus. IDCases. 2020;21:e00909.","journal-title":"IDCases"},{"issue":"3","key":"620_CR10","doi-asserted-by":"publisher","first-page":"e40168","DOI":"10.2196\/40168","volume":"5","author":"NG Sanchez","year":"2022","unstructured":"Sanchez NG, \u00c1vila Romay AA, Mart\u00ednez Luna E, Padilla Rodr\u00edguezAL. Cutaneous angiomyolipoma-A distinct entity that should be separated from classic angiomyolipoma: complete review of existing cases and defining fundamental features. JMIR Dermatol. 2022;5(3):e40168. https:\/\/doi.org\/10.2196\/40168. PMID: 37632898; PMCID: PMC10334929.","journal-title":"JMIR Dermatol"},{"issue":"6","key":"620_CR11","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1128\/AAC.00104-12","volume":"53","author":"J D\u00edaz-Delf\u00edn","year":"2012","unstructured":"D\u00edaz-Delf\u00edn J, Domingo P, Mateo MG, Gutierrez MDM, Domingo JC, Giralt M, Villarroya F. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother. 2012;53(6):3369\u201375. https:\/\/doi.org\/10.1128\/AAC.00104-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"620_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fonc.2020.00806","volume":"10","author":"G Barillari","year":"2020","unstructured":"Barillari G. The anti-angiogenic effects of anti-human immunodeficiency virus drugs. Front Oncol. 2020;10:806. https:\/\/doi.org\/10.3389\/fonc.2020.00806.","journal-title":"Front Oncol"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00620-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00620-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:08:32Z","timestamp":1715407712000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00620-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00620-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3994717\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a case report that does not meet the definition of research as defined by DHHS. IRB approval is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}